6 news items
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
BLRX
30 May 24
and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
BLRX
28 May 24
cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
BLRX
24 May 24
results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
BLRX
17 May 24
cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BLRX
6 May 24
and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results
e78dd541 5h
BLRX
17 Apr 24
of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements
- Prev
- 1
- Next